# Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia

**Authors:** Evgenii Shumilov, Paolo Mazzeo, Marcel Trautmann, Lena Levien, Kerstin Menck, Katharina Richter, Katharina Markus, Lena Ries, Detlef Haase, Elena Oberle, Philipp Berning, Wolfgang Hartmann, Philipp Ströbel, Andrea Kerkhoff, Georg Lenz, Gerald Wulf, Raphael Koch

PMC · DOI: 10.1007/s00277-025-06230-3 · Annals of Hematology · 2025-02-06

## TL;DR

This study identifies MCL-1 as a potential therapeutic target in a subset of T-cell large granular lymphocytic leukemia patients through functional apoptosis profiling.

## Contribution

The study introduces functional apoptosis profiling to uncover targetable anti-apoptotic vulnerabilities in T-LGLL cells.

## Key findings

- CD8+ T-LGLL cells in 50% of patients showed a strong dependence on MCL-1.
- AZD-5991 induced apoptosis in T-LGLL cells with enhanced MCL-1 dependence.
- T-LGLL exhibits clinical, genetic, and functional heterogeneity.

## Abstract

T-cell large granular lymphocytic leukemia (T-LGLL) is a rare hematologic neoplasm characterized by clonal expansion of CD3 + cytotoxic T lymphocytes and a highly heterogeneous clinical course. Conventional therapy primarily includes immunosuppressive regimen. However, optimal front-line approaches still need to be defined and refractory disease remains a clinical challenge. Thus, we here aimed to explore functional dependencies of T-LGLL as a basis for personalized therapeutic strategies. We performed functional apoptosis profiling and ex vivo drug treatment in a series of 8 clinically and genetically characterized T-LGLL patients from two German University hospitals. Our series of patients underscored the clinical and genetic heterogeneity of the disease. Genetically, only 2 patients harbored a STAT3 mutation. To identify targetable anti-apoptotic mechanisms, we performed selective functional BH3 profiling on the patients’ CD8 + T-cells harboring the malignant T-LGLL cells versus the same patients’ normal CD4 + T-cells. CD8 + cells in 50% of the patients (4/8) demonstrated a dominant functional dependence on MCL-1 as compared to the same patients’ normal T-cells. Accordingly, CD8 + T-LGLL cells from patients with enhanced MCL1 dependence significantly responded to AZD-5991 ex vivo while no response was observed in the remaining samples lacking enhanced MCL-1 dependence. Across clinically and genetically heterogeneous cases of T-LGLL, functional apoptosis profiling identified patients with CD8 + T-LGLL cells harboring a dominant dependence on MCL-1 as a potential therapeutic target.

The online version contains supplementary material available at 10.1007/s00277-025-06230-3.

Our study highlights the clinical, genetic and functional heterogeneity of T-LGLL and provides an approach to decipher targetable anti-apoptotic mechanisms. In our series of T-LGLL patients, we provide insight in the heterogeneous functional dependence of T-LGLL cells on MCL-1 and effective induction of apoptosis using AZD-5991 in T-LGLL cells with enhanced MCL-1 dependence.

The online version contains supplementary material available at 10.1007/s00277-025-06230-3.

## Linked entities

- **Genes:** STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774], MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170]
- **Chemicals:** AZD-5991 (PubChem CID 131634760)
- **Diseases:** T-cell large granular lymphocytic leukemia (MONDO:0019469)

## Full-text entities

- **Genes:** MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** hematologic neoplasm (MESH:D019337), T-LGLL (MESH:D054066)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11868225/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11868225/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC11868225/full.md

---
Source: https://tomesphere.com/paper/PMC11868225